Tetrahedron Letters, Vol. 26, No. 44, pp 5385-5388, 1985 OC Printed in Great Britain ©1

0040-4039/85 \$3.00 + .00 ©1985 Pergamon Press Ltd.

## OXIDATIVE CYCLIZATION OF β,γ-UNSATURATED O-ACYL HYDROXAMATES TO β-LACTAMS

G. Rajendra and Marvin J. Miller\*\*

Department of Chemistry, University of Notre Dame Notre Dame, IN 46556 USA

<u>Summary</u>: Reaction of O-Acyl vinylacetohydroxamates with bromine and base in aqueous acetonitrile provides a direct route to substituted  $4-(bromomethyl)-N-hydroxy \beta-lactams.$ 

The structural diversity of the many recently discovered  $\beta$ -lactam antibiotics has prompted the search for versatile and efficient syntheses of variously substituted  $\beta$ lactams.<sup>1</sup> 4-(Halomethyl)-2-azetidinones 1 are useful intermediates for the synthesis of nuclear analogues of penicillins and cephalosporins,<sup>2a</sup> carbapenems,<sup>2b</sup> and functionalized monocyclic  $\beta$ -lactams.<sup>2c</sup> However, the 4-(halomethyl) group is usually introduced by a multistep sequence after synthesis of the  $\beta$ -lactam ring system.<sup>2</sup> Because of the recent demonstration of the significant biological activity of substituted N-hydroxy  $\beta$ -lactams (oxamazins 3),<sup>3a-c</sup> we were especially interested in developing an efficient route to 4-(halomethyl)-N-hydroxy-2-azetidinones 2. Herein, we report the direct oxidative cyclization of substituted  $\beta$ , $\gamma$ -unsaturated hydroxamates to the corresponding substituted 4-(bromomethyl)-N-hydroxy  $\beta$ -lactams 10 (Scheme 2).



Although halolactonizations and related oxidative cyclizations of olefins are well known,<sup>4a,b</sup> early attempts to form lactams from olefins by similar procedures produced the lactones from the corresponding intermediate cyclic imidates instead.<sup>4c,d</sup> Recently, however, several efficient oxidative cyclizations of olefinic amides to lactams have been reported.<sup>5a-c,6a,b</sup> Especially interesting was Ganem's observation<sup>6a</sup> that the lowered pK of the carboxamide group of  $\beta$ , $\gamma$ -unsaturated N-tosyl amides **4** promoted bromine induced oxidative cyclizations to  $\beta$ -lactams. Our previous success in utilizing the acidity of O-substituted hydroxamates to facilitate cyclization of  $\beta$ -hydroxy and  $\beta$ -halohydroxamates to  $\beta$ -lactams,<sup>7</sup> encouraged us to study the oxidative cyclization of  $\beta$ , $\gamma$ -unsaturated hydroxamates as a route to the desired 4-(halomethyl)-N-hydroxy-2-azetidinone derivatives **2.** Since O-benzyl hydroxamates

5385

(pK~9-10) had functioned so well in our previous work,<sup>7</sup> we first attempted oxidative cyclizations of 0-benzyl vinyl acetohydroxamate **6**. This substrate was readily prepared by DCC/N-hydroxy succinimide activation of vinyl acetic acid  $5^8$  followed by reaction of 0-benzylhydroxylamine (Scheme 1). Unfortunately, all attempts to convert **6** to the  $\beta$ -lactam **7** by the use of halolactonization or mercuration conditions resulted in either formation of complex mixtures or recovery of starting materials.

Scheme 1



Although they are prone to Lossen rearrangement,<sup>9</sup> the increased acidity of 0-acyl hydroxamates (pK 6-7)<sup>7,9</sup> prompted us to attempt the oxidative cyclization of 0-acylhydroxamates **9a-d.** Since 0-acetyl and other 0-acyl hydroxylamines require multistep syntheses and are often unstable,<sup>9</sup> we developed the alternate route to **9a-d** shown in Scheme 2.<sup>10</sup> Indeed, subjection of the 0-acetyl derivative **9a** to Ganem's cyclization conditions  $(K_2CO_3, Br_2, H_20:CH_2Cl_2 (1:1), 5 min)$  provided the desired  $\beta$ -lactam **10a** in 73% isolated yield, with no detectable Lossen rearrangement products. Unfortunately the 0-acetyl  $\beta$ -lactam **10a** itself was unstable upon storage at room temperature longer than one day.

In order to test the generality of this oxidative cyclization, and to obtain stable  $\beta$ -lactams suitable for eventual further elaboration, several other hydroxamates (**9b-d**) were prepared and studied. Suprisingly, subjection of **9b-d** to the same conditions used for **9a** produced mixtures containing little or no  $\beta$ -lactam products. After studying several different solvent systems (CH<sub>2</sub>Cl<sub>2</sub>, THF, CH<sub>3</sub>OH, CH<sub>3</sub>CN, all with or without added H<sub>2</sub>O), 5-10% aqueous CH<sub>3</sub>CN was found to promote efficient cyclization of all hydroxamates **9a-d**<sup>10</sup> to the corresponding  $\beta$ -lactams **10a-d**<sup>10</sup> (75-90% yields) upon treatment with Br<sub>2</sub>/base under carefully controlled conditions.





Preparative scale procedures were developed for the series 9d + 10d + 11 since the hydroxamate 9d is a stable crystalline solid and the  $\beta$ -lactam 10d can be readily converted to the desired N-hydroxy  $\beta$ -lactam 11 by catalytic hydrogenation. Thus, 10 ml of vinyl acetic acid (5, 117.7 mmole) was added to a dry flask fitted with a stir bar and CaCl<sub>2</sub> drying tube. The flask was cooled to 0°C and 11.2 ml (109 mole %) of oxalyl chloride was added slowly (neat). The mixture was stirred at 0°C for 2 h and then at room temperature for 40-48 h. The resulting pale yellow liquid was added over a period of 5 to 8 min to a premixed and cooled (0°C) solution of 8.2 g (100 mole %) of H\_NOH+HCl and 19.9g (205 mole %) of KOH (prepared separately in 100 and 75 ml of  $CH_{2}OH$  respectively). The cooling bath was removed and the mixture was allowed to stir for 15-20 min. Filtration and concentration gave the crude hydroxamate **8** as a pale yellow oil. The oil was dissolved in 250 ml of dry THF, cooled to 0°C and 10 ml (105 mole %) of pyridine was added with stirring. After 5 min, 18.6 ml (105 mole % at 95% purity) of neat carbobenzoxy chloride was added over 30 min. The solution was stirred for another 60-90 min at RT and then filtered. The filtrate was concentrated to one fourth of its volume, taken up in ethyl acetate, and washed successively with three portions of  $H_2O$ , two portions of 1% HCl and two portions of brine. After drying over  $MgSO_4$ , filtration, evaporation and recrystallization from ethyl acetate - hexanes, hydroxamate 9d was obtained in 82-87% overall yield from vinyl acetic acid 5.

To a solution of the hydroxamate 9d (10-15 mmol) in CH<sub>3</sub>CN (~0.05 mmol of 9d/ml) was added 105 mole % of solid K<sub>2</sub>CO<sub>3</sub> followed by 5-10 volume % of H<sub>2</sub>O. The mixture was stirred vigorously for 20-30 sec, then 110 mole % of Br<sub>2</sub> in CH<sub>3</sub>CN (1 mmol/ml) was added through a dropping funnel over a period of 2-4 min with continued <u>vigorous stirring</u>. After the addition, the mixture was stirred for 1 min before being transferred to a separatory funnel containing ethyl acetate (10 ml/mmol of starting 9d). The mixture was then successively washed with H<sub>2</sub>O, 10% Na<sub>2</sub>SO<sub>3</sub> and brine before drying over MgSO<sub>4</sub>, filtration, chromatography (silica/ethyl acetate - hexane) and crystallization (ethyl acetate - hexanes) to provide 10d in 80-90% yield. Standard hydrogenation (H<sub>2</sub>,Pd-C/MeOH) provided the N-hydroxy *B*-lactam 11 (> 90%).

Thus, oxidative cyclization of  $0-acyl-\beta,\gamma$ -unsaturated hydroxamates **9** under carefully controlled conditions provides an efficient route to substituted 4-(bromomethyl)-N-hydroxy-2-azetidinones **10**. Extensions to the synthesis of a variety of 3- and 4-substituted monocyclic and bicyclic  $\beta$ -lactams will be described subsequently.

Acknowledgements:

We are grateful for the financial support of NIH and Eli Lilly and Co. The 300 MHz NMR system used was purchased by grants from NIH and the University of Notre Dame. References

<sup>‡</sup>Fellow of the Alfred P. Sloan Foundation (1981~1985). Recipient of an NIH Research Career Development Award (1983-1988).

- a) Labia, R.; Morin, C. J. Antibiotics 1984, 37, 1103.
   b) "Chemistry and Biology of β-Lactam Antibiotics," Morin, R. B. and Gorman, M. (Eds). Vol 1-3, Academic Press, NY, 1982.
- a) Huffman, W. F.; Holden, K. G.; Buckley III, T. F.; Gleason, J. G.; Wu, L. J. Amer. <u>Chem. Soc. 1977, 99</u>, 2352. b) Salzmann, T. N.; Ratcliffe, R. W.; Christensen, B. G.; Bouffard, F. A. J. Amer. Chem. Soc. 1980, 102, 6161. c) Miller, M. J.; Bajwa, J. S.; Mattingly, P. G.; Peterson, K. J. Org. Chem. 1982, 47, 4928.
- a) Woulfe, S. R.; Miller, M. J. <u>Tet. Lett. 1984</u>, <u>25</u>, 3293. b) Woulfe, S. R.; Miller, M. J. <u>J. Med. Chem</u>. (in press). c) Breuer, H.; Straub, H.; Trenuer, U. D.; Drossard, J.-M.; Höhn, H.; Lindner, K. R. <u>J. Antibiotics 1985</u>, <u>38</u>, 813.
- 4. a) Bartlett, P. A. Tetrahedron <u>1980</u>, <u>36</u>, 2. b) Dowle, M. D.; Davies, D. I. <u>Chem. Soc.</u>, <u>Rev.</u>, <u>1979</u>, <u>8</u>, 171. c) Corey, E. J.; Fleet, G. W. J.; Kato, M. <u>Tet. Lett. 1973</u>, 3963. d) Clive, D. L. J.; Wong, C. K.; Kiel, W. A.; Menchen, S. M. <u>J. Chem. Soc. Chem. Commum</u>. <u>1978</u>, 379.
- a) Knapp, S.; Rodrigues, K. E.; Levorse, A. T.; Ornaf, R. M. <u>Tet. Lett. 1985</u>, 1803. b) Danishefsky, S.; Taniyama, E.; Webb II, R. R. <u>Tet. Lett. 1983</u>, 11. c) Kozikowski, A. P.; Scripko, J. <u>Tet. Lett.</u>, <u>1983</u>, 2051.
- a) Biloski, A. J.; Wood, R. D.; Ganem, B. J. Amer. Chem. Soc. 1982, 104, 3233. b) Ihara, M.; Haga, Y.; Yonekura, M.; Ohsawa, T.; Fukumoto, K.; Kametani, T. J. Amer. Chem. Soc. 1983, 105, 7345.
- Miller, M. J.; Mattingly, P. G.; Morrison, M. A.; Kerwin, J. F. Jr. <u>J. Amer. Chem. Soc.</u> <u>1980</u>, <u>102</u>, 7026.
- Of the several sources tried, vinyl acetic acid obtained from Fluka was found to be isomerically and chemically most pure.
- 9. Miller, M. J.; DeBons, F. E.; Loudon, G. M. J. Org. Chem. 1977, 42, 1750.
- 10. Selected characterization data includes (90 MHz NMR, unless otherwise specified):
  8: IR, 3600-2500 v broad, 1640 cm<sup>-1</sup>; NMR, 2.96 (d, 2H), 4.94-5.28 (m, 2H), 5.66-6.25 (m, 1H), 9-10(b, 1H).
  9a: IR, 3200 broad, 1800, 1680 cm<sup>-1</sup>; NMR, 2.16 (s, 3H), 2.96-3.16 (d, 2H), 5.1-5.37 (m, 2H), 5.68-6.2 (m, 1H), 10.2-10.8 (b, 1H).
  9b NMR, 1.23 (d, 6H), 2.76 (Sept, 1H), 3.0-3.17 (d, 2H), 5.1-5.33 (m, 2H), 5.7-6.20 (m, 1H).
  9c NMR, 1.25 (s, 9H), 3.00-3.23 (d, 2H).
  5.03-5.33 (m, 2H), 5.7-6.20 (m, 1H), 10.3 (b, 1H).
  9d Mp. 71-74°C; IR, 3210 br, 1800, 1690 cm<sup>-1</sup>; NMR (200 MHz), 3.025-3.14 (d, 2H), 5.2-5.35 (m, 4H), 5.8-6.03 (m, 1H), 7.38 (s, 5H), 8.85 (b, 1H).
  10a: IR, 1820, 1780 cm<sup>-1</sup>; NMR, 2.22 (s, 3H), 2.62-3.24 (ddd, 2H), 3.43-3.8 (m 2H), 4.22-4.44 (m, 1H).
  10b: NMR, 1.25 (d, 6H), 2.43-2.96 (m, 3H), 3.45-3.83 (m, 2H), 4.23-4.5 (m, 1H).
  10c: NMR, 1.30 (s, 9H), 2.56-3.33 (ddd, 2H), 3.36-3.83 (m, 2H), 4.23-4.5 (m, 1H).
  10c: NMR, 1.30 (s, 9H), 2.56-3.33 (ddd, 2H), 3.36-3.83 (m, 2H), 4.23-4.5 (m, 1H).
  10c: NMR, 1.30 (s, 9H), 2.56-3.33 (ddd, 2H), 3.36-3.83 (m, 2H), 4.23-4.5 (m, 1H).
  10c: NMR, 1.30 (s, 9H), 2.56-3.33 (ddd, 2H), 3.36-3.83 (m, 2H), 4.23-4.5 (m, 1H).
  10c: NMR, 1.30 (s, 9H), 2.56-3.33 (ddd, 2H), 3.36-3.83 (m, 2H), 4.23-4.5 (m, 1H).
  10c: NMR, 1.30 (s, 9H), 2.56-3.33 (ddd, 2H), 7.39 (s, 5H).
  11: IR, 3700-2400 v broad, 1750 cm<sup>-1</sup>; NMR, 2.47-3.07 (ddd, 2H), 3.13-3.90 (m, 2H), 4.03-4.3 (m, 1H), 8.3-9.0 (b, 1H).

(Received in USA 7 August 1985)